FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB 3235Number: 0287
Expires: November 30
2011
Estimated average
burden hours per
response... 0.5

(Print or Type Respo	nses)									
Name and Addres Rhodes John B	Symbol	Tonix Pharmaceuticals Holding Corp.				rp.	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)X_ Director 10% Owner 0fficer (give title Other (specify below)			
(Last) C/O TONIX PHA HOLDING COR AVENUE, SUIT	LS (Month/Day	3. Date of Earliest Transaction (Month/Day/Year) 04/26/2013					elow)			
NEW YORK, NY		4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	Table I -	Non-De	riva	tive Secur	ities A	Acqui	ired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				6. Ownership Form: Direct (D)	Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	or Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	04/26/2013		С		166,667	A	\$ 0.4	1,268,603	D	
Reminder: Report or directly or indirectly.		ach class of securiti	es benefi	cially	y owned					
				in re	formation equired to	res	ntaine pond	d to the collection d in this form are r unless the form dis control number.	not	SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	Transaction	3A. Deemed	4.		5. Number of		Date Exercisable and		7. Title and Amount		Price of	Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transac	tion	Derivative		Expiration Date		of Underlying		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Sec	urities	(Month/Day/Year)		Securities		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)				(Instr. 3 and 4)		(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					or Disposed							Owned	Security:	(Instr. 4)
	Security					of (D)						Following	Direct (D)	
						(Ins	tr. 3, 4,						Reported	or Indirect	
						and 5)							Transaction(s)	(I)	
											Amount		(Instr. 4)	(Instr. 4)	
								Date	Expiration		or				
									Date	Title	Number				
				Code	V	(A)	(D)				of Shares				
Warrants	\$ 0.4	04/26/2013		С			166,667	12/04/2012	12/04/2013	Common Stock	166,667	\$0	383,333	D	

Reporting Owners

Reporting Owner Name / Address		Relationships						
		10% Owner	Officer	Other				
Rhodes John B								
C/O TONIX PHARMACEUTICALS HOLDING CORP.	X							
509 MADISON AVENUE, SUITE 306	Λ							
NEW YORK, NY 10022								

Signatures

/s/ John Rhodes	04/29/2013
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.